Alerinit

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alerinit

Quick Facts

Property Description
Active ingredient Levocetirizine dihydrochloride
Form Film-coated tablets, oral solution
Pharmacological class Second-generation Antihistamine (H1-receptor antagonist)
General purpose Relief from allergic symptoms
Origin Synthetic (purified R-enantiomer)

Alerinit is a synthetic medicinal product containing the active substance Levocetirizine dihydrochloride and belongs to the pharmacological group of antihistamines. Its primary function is to serve as an antiallergic agent, providing systemic relief by modulating the body's response to allergy-causing substances.


What Type of Medicine is Alerinit (Levocetirizine)?

Alerinit is classified as a second-generation antihistamine drug, functioning as a highly selective peripheral H1-receptor antagonist. The efficacy of this classification is clinically recognized across numerous pharmacological studies, confirming its ability to stabilize the allergic response.

The active component, Levocetirizine, is a synthetic compound and is structurally defined as the purified, active R-enantiomer of the older drug cetirizine. This specific structure places it in the second-generation category, a class widely favored because its chemical properties show a lower tendency to cross the blood-brain barrier compared to first-generation antihistamines. Its type is that of a single-ingredient product, containing only Levocetirizine dihydrochloride to provide its targeted therapeutic effect.


Composition and Available Forms of Alerinit

The active ingredient in Alerinit is Levocetirizine dihydrochloride, and it is available for oral administration in high-level dosage forms, specifically film-coated tablets and an oral solution. The provision of the liquid form is often utilized for patient groups, such as children, who may have difficulty swallowing tablets.

Both forms deliver the same active ingredient for systemic absorption. The tablets utilize solid excipients, while the oral solution uses an aqueous vehicle. A comprehensive overview of levocetirizine's properties confirms its mechanism of action is significantly centered on the selective binding to H1 receptors.


General Purpose of Alerinit as an Antiallergic Agent

The general purpose of Alerinit is to provide relief from allergic symptoms by controlling the effects of the natural chemical histamine in the body. The medication achieves this by acting as a selective peripheral H1-receptor antagonist, which competitively blocks the binding sites that histamine uses to trigger symptoms. By interrupting this chain of events, Alerinit minimizes the physical manifestations of the immune system's overreaction to allergens, thereby functioning as an effective antiallergic agent.

What side effects are possible with Alerinit?

Possible Side Effects and Safety Information

The safety profile of Alerinit (Levocetirizine dihydrochloride) is structured according to regulatory frequency standards, classifying reported adverse reactions based on their statistical likelihood as defined in official government documents. These reactions are also grouped by the physiological system affected.

Common and Uncommon Adverse Reactions

Adverse reactions classified as Common (affecting 1 to 10 users in 100) often involve the nervous and general systems. The most frequently documented effects include Somnolence (drowsiness), Headache, Fatigue, and Dry mouth. Somnolence is an effect noted in regulatory documents that may be more prominent at the beginning of treatment. Uncommon reactions (affecting 1 to 10 users in 1,000) may include Abdominal pain and Asthenia (lack of energy).

System Organ Class Common Reactions
Nervous System Somnolence, Headache
General Disorders Fatigue, Asthenia
Gastrointestinal Dry mouth, Abdominal pain

Serious Adverse Reactions and Safety Constraints

Regulatory safety information documents rare but serious adverse reactions that have been reported. These include immediate-type Hypersensitivity reactions such as Anaphylaxis and Angioneurotic oedema (rapid swelling). Other documented serious effects include Convulsions (Seizures), Hepatitis, and Urinary retention.

Official safety constraints are noted for specific patient populations. The medication is contraindicated in individuals with severe renal impairment (kidney disease). Additionally, regulatory documents note that older adults may have an increased risk of sedation and urinary retention, and caution is noted for the paediatric population regarding dose-related sedation. The official label also highlights the risk of increased Central Nervous System (CNS) effects when used alongside alcohol or other CNS depressants.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This information details the officially documented overdose profile for Levocetirizine dihydrochloride, based exclusively on government regulatory sources.

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations The primary clinical manifestation in adults is excessive somnolence (drowsiness).
Physiological Systems Affected Central Nervous System (CNS) effects are the documented primary focus, manifesting as somnolence and agitation.
Population-Specific Overdose Notes The difference in initial presentation (agitation) is an explicitly stated consideration for pediatric patients.
When Immediate Medical Help Is Required Urgent medical help is required upon any suspected overdose event. Contact a Poison Control Center is the mandated action.

Overdose Management & Constraints

Classification Official Regulatory Statement
Antidote Availability No specific antidote is known for levocetirizine overdose.
Management Measures Treatment is specified to be symptomatic and supportive. Hemodialysis is ineffective for the removal of the drug.

Summary of Regulator-Mandated Action

The official labeling requires individuals to seek emergency medical attention immediately in the event of a suspected overdose. The regulatory guidance establishes that management is limited to supportive care, emphasizing that the drug is not dialyzable and that no specific antidote exists to reverse the effects of an overdose.

Therapeutic Uses of Alerinit

Quick Facts

  • Relief from Allergic Symptoms: Intended to address symptoms related to allergic conditions.
  • Seasonal and Year-Round Allergies: Used for managing symptoms of allergic rhinitis.
  • Skin Manifestations: Helps mitigate symptoms associated with chronic hives (urticaria).

What Alerinit Treats: Main Uses and Benefits

Alerinit (levocetirizine dihydrochloride) is used in the therapeutic management of symptoms associated with specific allergic conditions. The primary clinical uses involve providing relief for both seasonal and year-round allergic rhinitis, which may involve manifestations such as sneezing, a runny nose, an itchy nose, and watery eyes.

Additionally, this medication is utilized for the management of symptoms linked to chronic idiopathic urticaria (hives), which includes mitigating itchiness, swelling, and the appearance of rash or redness on the skin. The medication is intended to help reduce the presence of these uncomfortable allergy symptoms to support typical daily activities.

These therapeutic applications align with the established medical uses for this class of compound.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

The eligibility for using Alerinit (levocetirizine dihydrochloride) is strictly defined by regulatory documents based on a patient's age, specific health conditions, and physiological status.

Category Official Regulatory Statement
Populations for whom use is allowed Approved for adults and adolescents 12 years of age and older. Approved for children 6 months of age and older, with form-specific rules (e.g., oral solution for younger children).
Populations for whom use is contraindicated Patients with end-stage renal disease (creatinine clearance < 10 mL/min) or those undergoing hemodialysis. Also contraindicated for pediatric patients (6 months to 11 years) with any degree of impaired renal function.
Age-related limitations Safety and efficacy have not been established in infants younger than 6 months of age. The film-coated tablet is not recommended for children under 6 years.
Condition-specific eligibility Use in patients 12 years and older with mild to severe renal impairment is permitted only with adjusted dosing based on the degree of reduced kidney function. No adjustment is required for solely hepatic impairment.
Pregnancy and lactation status Not recommended during pregnancy or lactation; use should generally be avoided or considered only if clearly needed.

Eligibility-Related Restrictions

Conditional use is required for older adults, whose dosage must be adjusted based on an assessment of renal function. The medicine should also be used with caution in patients with predisposing factors for urinary retention, such as prostatic hyperplasia or spinal cord lesions, as stated in official labeling.

What should I know about interactions with other medicines?

Pharmacodynamic and CNS Effects

Official regulatory information indicates that co-administration with alcohol or other Central Nervous System (CNS) depressants may cause an additive impairment, leading to additional reductions in alertness and central nervous system performance. Due to this established pharmacodynamic effect, concurrent use with these substances must be avoided as an interaction-related restriction.


Pharmacokinetic Interactions and Metabolism

Levocetirizine's primary elimination pathway is through the kidneys via glomerular filtration and active tubular secretion. Studies examining the racemate, cetirizine, showed that Ritonavir increases drug exposure (AUC) and Theophylline causes a minor decrease in clearance. Levocetirizine undergoes minimal hepatic metabolism (less than 14%), which confirms it is unlikely to cause or be subject to clinically relevant CYP450 enzyme interactions as stated in regulatory documents.


Food and Population Constraints

Co-administration with food does not alter the overall amount of drug absorbed (extent), but the rate of absorption is officially documented to be decreased. Given the drug's essential reliance on renal elimination, severe renal impairment or End-Stage Renal Disease (ESRD) is formally listed as a contraindication in the prescribing information because it significantly reduces clearance, increasing the risk of drug accumulation in the body.

Mechanism of Action

How Alerinit Works

Alerinit functions through the modulation of specific biological pathways, with its action centered around two primary mechanistic domains.


Histamine H1 Receptor Inverse Agonism

Alerinit primarily targets the Histamine H1 receptor. The drug acts as an inverse agonist, binding to and stabilizing the receptor in an inactive conformation. This stabilization limits the capacity of the natural signaling molecule, histamine, to trigger receptor activation. This molecular blockade results in the modulation of signals related to increased microvascular permeability and localized nerve stimulation.


Modulation of Inflammatory Cell Recruitment

This secondary domain covers Alerinit's influence on the cellular components of processes involving high mediator release. The mechanism involves the modulation of the movement and activity of specific inflammatory white blood cells, such as eosinophils, at sites of mediator release. This cellular-level modulation functions alongside the receptor action to influence biological processes linked to changes in microvascular permeability and tissue dynamics.

Dosage and Administration Information

The administration of Alerinit (levocetirizine dihydrochloride) follows specific parameters for proper systemic use. The medication is strictly administered by the oral route, available as film-coated tablets (typically 5 mg strength) and an oral solution.


Standard Dosing and Frequency

The standard dosage for adults and adolescents (12–64 years) is 5 mg taken once daily in a single intake. This quantity is also defined as the maximum recommended daily dose. It is generally recommended that the medication be administered in the evening. A key administration principle is flexibility regarding food intake; Alerinit may be consumed with or without food. The treatment pattern is defined as either persistent, continuous use for chronic conditions, or intermittent, as-needed use for temporary seasonal symptoms.


Population-Specific Adjustments

Specific dose adjustments are required for certain populations. Pediatric patients aged 6 to 11 years receive 2.5 mg once daily, and children 6 months to 5 years receive 1.25 mg once daily; the oral solution is necessary for these younger patients to achieve accurate dosing. For older adults and patients with impaired kidney function, the dose is adjusted based on the degree of renal impairment. This adjustment may involve lowering the dose or altering the dosing frequency to less than once per day. No specific dose change is required for patients with isolated hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alerinit

Evidence Supporting Use in Allergic Rhinitis

The research for Alerinit (levocetirizine) primarily addresses conditions characterized by fluctuating or episodic manifestations, such as Seasonal and Perennial Allergic Rhinitis (hay fever). The primary research approach involved numerous short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms and primarily included patients with allergic rhinitis symptoms.

Researchers examined outcomes related to physical discomfort by measuring changes in Total Symptom Scores (TSS). These composite scores monitored physiological strain linked to inflammatory states, such as sneezing, runny nose, and watery eyes, over defined time intervals. The findings describe patterns observed in these short-term studies, and the evidence helps contextualize how symptoms evolved in the study populations.

Evidence Supporting Use in Chronic Idiopathic Urticaria (Hives)

Alerinit was evaluated for conditions involving periods of heightened symptoms, specifically Chronic Idiopathic Urticaria (CIU), which is marked by functional limitations such as hives and intense itchiness. The research base for this indication is anchored by Randomized Controlled Trials (RCTs) that typically spanned intermediate durations of approximately four to six weeks.

These studies examined urticaria symptom scores. These patient-reported outcomes describing perceived discomfort captured phases of heightened symptom activity, such as the size and frequency of wheals and the intensity of pruritus (itchiness). Studies report how symptoms evolved in the observed populations, as measured by these symptom scores. Findings indicate changes measured during the study period, and the evidence contributes to the broader evidence landscape.

Limitations and Research Gaps

While the research base is structured around short-term outcomes, follow-up durations were limited in most of the core efficacy studies, meaning long-term effects are not fully established. Research provides insight into short-term changes, but long-term outcomes and the maintenance of effects over full allergy seasons are not well characterized.

Research has explored the use of Alerinit across different age groups, including Adults and specific Pediatric Patients. However, data for certain subgroups, such as those with multiple coexisting health conditions, remain insufficient. Research does not determine whether an individual will respond similarly to the group patterns observed in the studies, as study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Alerinit (FAQ)

Q: Do the side effects of Alerinit usually go away after the first few days?

Regulatory information indicates that common effects, such as somnolence (drowsiness), may be more noticeable during the initial phase of treatment. Patients with questions about how long specific effects may last should consult their healthcare provider.


Q: How quickly does Alerinit typically start to work after taking it?

Based on findings from clinical studies, symptomatic improvement has been observed as early as one day after a patient starts taking Alerinit. This timeline reflects the patterns observed in the clinical trial data supporting its use.


Q: How long does the effect of one dose of Alerinit last?

Alerinit is typically taken in a once-daily dosing pattern. Clinical studies supporting its use report that symptomatic improvement was maintained over the full 24-hour interval between doses.


Q: Can Alerinit interfere with driving or operating machinery?

Due to the potential for drowsiness, official regulatory warnings advise against engaging in activities that require complete mental alertness. This includes driving a car or operating heavy machinery, until an individual fully understands how Alerinit affects them.


Q: Is Alerinit addictive or habit-forming?

Official safety assessments conducted by regulatory bodies indicate that Alerinit is not considered to be habit-forming. Therefore, it is not expected to cause physical dependency.


Q: Is Alerinit considered safe for use during pregnancy, based on current regulatory warnings?

The drug is classified by the US FDA as Pregnancy Category B. This classification indicates that animal studies have not shown harm to the fetus, but there are no comprehensive studies available for pregnant individuals.


Q: What happens if I stop taking Alerinit suddenly?

Regulatory documents contain a specific warning about the potential for severe itching, known as pruritus, that may occur within a few days after stopping the drug. This effect is particularly noted following long-term, daily use of the medication.


Q: Why might a patient need to have their blood monitored while on Alerinit?

While routine monitoring is not indicated for all patients, regulatory information notes a greater risk of adverse reactions for patients with impaired kidney function. Because of this risk, official documents require dose adjustment for those with impaired kidney function. Rare cases of liver inflammation (Hepatitis) have also been reported.


Q: Can people with liver issues take Alerinit?

Official information states that Alerinit is primarily eliminated by the kidneys, and no specific dose adjustment is required for patients who have only isolated hepatic (liver) impairment. Such considerations are typically addressed by a healthcare provider.


Q: Does Alerinit have a black box warning in the US regulatory documents?

The drug does not carry a Black Box Warning. This specific warning represents the most stringent warning level required by the US Food and Drug Administration (FDA) for drug labels.


Q: Is Alerinit a short-term or long-term medication?

Clinical trial evidence supports its use for various durations depending on the condition. This includes short-term use, such as for two weeks for seasonal allergic rhinitis, and longer periods, with studies extending up to six months for perennial allergic rhinitis or chronic urticaria.


Q: How long is a typical course of treatment with Alerinit?

The required duration of use varies based on the underlying condition. Clinical trials have supported use for two weeks for seasonal allergic rhinitis, while studies have extended up to six months for conditions like perennial allergic rhinitis or chronic idiopathic urticaria.


Q: Is there anything specific I should avoid eating or drinking while taking Alerinit?

Official warnings specifically advise against the concurrent use of alcohol. Regulatory information indicates that taking the medication alongside food may decrease the rate at which the drug is absorbed, although it does not affect the overall amount that enters the body.


Q: Does Alerinit contain lactose or gluten?

The inactive ingredients, or excipients, in Alerinit are detailed in the official composition section of the prescribing information. These details are typically included in the official prescribing information available from the manufacturer or pharmacist.


Q: Is Alerinit available without a prescription in any country?

The regulatory status of the drug varies globally. The active ingredient, levocetirizine, is available without a prescription (over the counter) in the United States and several other international countries.


Q: What are the main reasons Alerinit might be discontinued?

Official documentation notes that the drug should be stopped if serious adverse reactions occur, such as severe allergic reactions or convulsions, or if specific effects like urinary retention develop. It also notes risks associated with discontinuation following long-term use.


Q: Are there specific food groups that are commonly warned against when taking Alerinit?

Regulatory documents state that taking the medication with food does not alter the overall amount of drug absorbed but may decrease the rate of absorption. No specific food groups are formally warned against in the official prescribing information.


Q: How does the body generally process Alerinit (basic metabolism concept)?

Regulatory information indicates that the body minimally processes the drug through the liver, with less than 14% metabolism. Alerinit is primarily eliminated from the body by the kidneys.


Q: Are there any known severe allergic reactions associated with Alerinit?

Regulatory safety information documents rare but serious immediate-type hypersensitivity reactions. These reported reactions include anaphylaxis and angioneurotic oedema (rapid swelling).


Q: Is Alerinit known by any other name internationally?

Yes, the active ingredient in Alerinit, levocetirizine, is marketed internationally under various other brand names, depending on the country.

How should Alerinit be stored and disposed of?

How to Store and Dispose of Alerinit?

The storage of Alerinit (levocetirizine) is strictly defined by regulatory guidelines to maintain its quality. The product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original, tightly closed container and secured in a location away from moisture, excess heat, and light. It is mandatory to keep from freezing.

Child Safety and Disposal

The medication must always be stored out of the sight and reach of children.

To dispose of unused or expired Alerinit, do not throw it away via household waste or wastewater. Consult your pharmacist or follow local regulatory requirements for the proper disposal of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alerinit found in:

A-Z Index: